{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T05:22:20Z","timestamp":1793510540362,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,9,23]],"date-time":"2027-09-23T00:00:00Z","timestamp":1821657600000},"content-version":"am","delay-in-days":630,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016982","name":"Yamagata University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012819","name":"Egyptian Cultural and Educational Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.bmcl.2025.130416","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:40:48Z","timestamp":1758588048000},"page":"130416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Design, synthesis, and biological evaluation of novel 1,5-diarylpyrazole carboxamides with dual inhibition of EGFR and COX-2 for the treatment of cancer and inflammatory diseases"],"prefix":"10.1016","volume":"130","author":[{"given":"Osama M.","family":"Soltan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salah A.","family":"Abdel-Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal S.","family":"Abdelrahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Narumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abdel-Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai E.","family":"Shoman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Konno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2025.130416_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106273","article-title":"Novel pyrazole-based COX-2 inhibitors as potential anticancer agents: design, synthesis, cytotoxic effect against resistant cancer cells, cell cycle arrest, apoptosis induction and dual EGFR\/Topo-1 inhibition","volume":"131","author":"Halim","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bmcl.2025.130416_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129673","article-title":"Development of 1, 5-diarylpyrazoles as EGFR\/JNK-2 dual inhibitors: design, synthesis, moleecular docking, and bioactivity evaluation","volume":"102","author":"Soltan","year":"2024","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bmcl.2025.130416_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113768","article-title":"Molecular hybrids: a five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy","volume":"225","author":"Soltan","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmcl.2025.130416_bb0020","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1677\/erc.0.0080151","article-title":"The ErbB receptor tyrosine family as signal integrators","volume":"8","author":"Hynes","year":"2001","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.bmcl.2025.130416_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115674","article-title":"New series of isoxazole derivatives targeting EGFR-TK: synthesis, molecular modeling and antitumor evaluation","volume":"28","author":"Warda","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bmcl.2025.130416_bb0030","doi-asserted-by":"crossref","first-page":"25204","DOI":"10.1039\/D2RA04498F","article-title":"Novel quinoxaline derivatives as dual EGFR and COX-2 inhibitors: synthesis, molecular docking and biological evaluation as potential anticancer and anti-inflammatory agents","volume":"12","author":"Ahmed","year":"2022","journal-title":"RSC Adv."},{"key":"10.1016\/j.bmcl.2025.130416_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103132","article-title":"Thiohydantoin derivatives incorporating a pyrazole core: design, synthesis and biological evaluation as dual inhibitors of topoisomerase-I and cycloxygenase-2 with anti-cancer and anti-inflammatory activities","volume":"91","author":"Abdellatif","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bmcl.2025.130416_bb0040","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/384644a0","article-title":"Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents","volume":"384","author":"Kurumbail","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2025.130416_bb0045","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1074\/jbc.272.14.9280","article-title":"Conversion of prostaglandin G\/H synthase-1 into an enzyme sensitive to PGHS-2-selective inhibitors by a double His513\u2192 Arg and Ile523\u2192 Val mutation","volume":"272","author":"Wong","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bmcl.2025.130416_bb0050","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.bmc.2014.12.041","article-title":"Synthesis, biological evaluation and docking analysis of a new series of methylsulfonyl and sulfamoyl acetamides and ethyl acetates as potent COX-2 inhibitors","volume":"23","author":"Consalvi","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bmcl.2025.130416_bb0055","article-title":"A journey of celecoxib from pain to cancer","volume":"147","author":"Saxena","year":"2020","journal-title":"Prostaglandins OtherLiipid Mediators"},{"key":"10.1016\/j.bmcl.2025.130416_bb0060","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1021\/jm010458r","article-title":"Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models","volume":"45","author":"Palomer","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmcl.2025.130416_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112662","article-title":"Discovery of novel urea-diarylpyrazole hybrids as dual COX-2\/sEH inhibitors with improved anti-inflammatory activity and highly reduced cardiovascular risks","volume":"205","author":"Abdelazeem","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmcl.2025.130416_bb0070","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejmech.2019.03.008","article-title":"Design, synthesis and evaluation of novel diaryl-1, 5-diazoles derivatives bearing morpholine as potent dual COX-2\/5-LOX inhibitors and antitumor agents","volume":"169","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmcl.2025.130416_bb0075","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.ejmech.2014.12.023","article-title":"Recent advanced in bioactive systems containing pyrazole fused with a five membered heterocycle","volume":"97","author":"Raffa","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmcl.2025.130416_bb0080","doi-asserted-by":"crossref","first-page":"11397","DOI":"10.1074\/jbc.275.15.11397","article-title":"The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2","volume":"275","author":"Hsu","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bmcl.2025.130416_bb0085","first-page":"6045","article-title":"Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models","volume":"60","author":"Williams","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.bmcl.2025.130416_bb0090","doi-asserted-by":"crossref","first-page":"7908","DOI":"10.1038\/sj.onc.1203286","article-title":"The role of cyclooxygenases in inflammation, cancer, and development","volume":"18","author":"Williams","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.bmcl.2025.130416_bb0095","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/annonc\/mdf125","article-title":"Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention","volume":"13","author":"Davies","year":"2002","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bmcl.2025.130416_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-019-1600-7","article-title":"TFAP2B overexpression contributes to tumor growth and progression of thyroid cancer through the COX-2 signaling pathway","volume":"10","author":"Fu","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bmcl.2025.130416_bb0105","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1021\/jm200235u","article-title":"N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase II\u03b1 and induce apoptosis in G1\/S phase","volume":"54","author":"Baviskar","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmcl.2025.130416_bb0110","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bmcl.2015.11.040","article-title":"Design, synthesis and biological evaluation of pyrazolyl-nitroimidazole derivatives as potential EGFR\/HER-2 kinase inhibitors","volume":"26","author":"Tao","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bmcl.2025.130416_bb0115","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.bmcl.2007.12.035","article-title":"Novel 3-alkoxy-1H-pyrazolo [3, 4-d] pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors","volume":"18","author":"Ducray","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bmcl.2025.130416_bb0120","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.bmc.2013.01.074","article-title":"Discovery of N-[5-({2-[(cyclopropylcarbonyl) amino] imidazo [1, 2-b] pyridazin-6-yl} oxy)-2-methylphenyl]-1, 3-dimethyl-1H-pyrazole-5-carboxamide (TAK-593), a highly potent VEGFR2 kinase inhibitor","volume":"21","author":"Miyamoto","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bmcl.2025.130416_bb0125","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ejmech.2014.09.024","article-title":"Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors","volume":"86","author":"Yao","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmcl.2025.130416_bb0130","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1016\/j.bmc.2014.06.020","article-title":"Structure-based optimization and biological evaluation of trisubstituted pyrazole as a core structure of potent ROS1 kinase inhibitors","volume":"22","author":"Park","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bmcl.2025.130416_bb0135","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1021\/acs.jmedchem.7b01845","article-title":"Discovery of 1, 5-diphenylpyrazole-3-carboxamide derivatives as potent, reversible, and selective monoacylglycerol lipase (MAGL) inhibitors","volume":"61","author":"Aghazadeh Tabrizi","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmcl.2025.130416_bb0140","doi-asserted-by":"crossref","first-page":"42","DOI":"10.2174\/1871520620666200727093613","article-title":"Design, synthesis, molecular docking, and anticancer evaluation of Pyrazole linked Pyrazoline derivatives with Carbothioamide tail as EGFR kinase inhibitors","volume":"21","author":"Nawaz","year":"2021","journal-title":"Anti-Cancer Agents in Med Chem"},{"key":"10.1016\/j.bmcl.2025.130416_bb0145","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.bmc.2012.01.051","article-title":"Design, synthesis and biological evaluation of pyrazolyl-thiazolinone derivatives as potential EGFR and HER-2 kinase inhibitors","volume":"20","author":"Qiu","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bmcl.2025.130416_bb0150","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1517\/17460440902956636","article-title":"Drug hybridization strategies: before or after lead identification?","volume":"4","author":"Fraga","year":"2009","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.bmcl.2025.130416_bb0155","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.2174\/092986707781058805","article-title":"Molecular hybridization: a useful tool in the design of new drug prototypes","volume":"14","author":"Viegas-Junior","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bmcl.2025.130416_bb0160","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2174\/1389557517666161111110121","article-title":"Recent highlights on molecular hybrids potentially useful in central nervous system disorders","volume":"17","author":"Matias","year":"2017","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.bmcl.2025.130416_bb0165","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/1568026618666180221114515","article-title":"Bis-coumarin derivatives and their biological activities","volume":"18","author":"Ren","year":"2018","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bmcl.2025.130416_bb0170","doi-asserted-by":"crossref","first-page":"129","DOI":"10.7324\/JAPS.2020.102019","article-title":"Recent advancements in uracil and 5-fluorouracil hybrids as potential anticancer agents: a review","volume":"10","author":"Sanduja","year":"2020","journal-title":"J Applied Pharm Sci"},{"key":"10.1016\/j.bmcl.2025.130416_bb0175","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejmech.2015.11.013","article-title":"Discovery of novel hybrids of diaryl-1, 2, 4-triazoles and caffeic acid as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase for cancer therapy","volume":"108","author":"Cai","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmcl.2025.130416_bb0180","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1016\/j.bmc.2018.07.022","article-title":"Design and biological evaluation of novel hybrids of 1, 5-diarylpyrazole and Chrysin for selective COX-2 inhibition","volume":"26","author":"Ren","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bmcl.2025.130416_bb0185","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1016\/j.bmcl.2016.06.037","article-title":"Coumarin sulfonamides derivatives as potent and selective COX-2 inhibitors with efficacy in suppressing cancer proliferation and metastasis","volume":"26","author":"Lu","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bmcl.2025.130416_bb0190","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S0039-9140(97)00017-9","article-title":"A highly water-soluble disulfonated tetrazolium salt as a chromogenic indicator for NADH as well as cell viability","volume":"44","author":"Ishiyama","year":"1997","journal-title":"Talanta"},{"key":"10.1016\/j.bmcl.2025.130416_bb0195","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1016\/j.bmcl.2019.06.052","article-title":"Design, synthesis, and evaluation of a water soluble C5-monoketone type curcumin analogue as a potent amyloid \u03b2 aggregation inhibitor","volume":"29","author":"Hotsumi","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bmcl.2025.130416_bb0200","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.ejmech.2018.09.024","article-title":"Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat","volume":"158","author":"Chu-Farseeva","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmcl.2025.130416_bb0205","first-page":"7.19","article-title":"Darzynkiewicz, Flow cytometry of apoptosis","volume":"21, Chapter 7","author":"Pozarowski","year":"2003","journal-title":"Curr Protocols Cytom"},{"key":"10.1016\/j.bmcl.2025.130416_bb0210","doi-asserted-by":"crossref","first-page":"18662","DOI":"10.1021\/acsomega.0c01323","article-title":"2D-QSAR modeling and molecular docking studies on 1 H-Pyrazole-1-carbothioamide derivatives as EGFR kinase inhibitors","volume":"5","author":"Hajalsiddig","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.bmcl.2025.130416_bb0215","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ejmech.2019.05.029","article-title":"Design, synthesis and biological evaluation of novel substituted purine isosters as EGFR kinase inhibitors, with promising pharmacokinetic profile and in vivo efficacy","volume":"176","author":"Gavriil","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmcl.2025.130416_bb0220","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.bioorg.2018.07.015","article-title":"Dual EGFR\/HER2 inhibitors and apoptosis inducers: new benzo [g] quinazoline derivatives bearing benzenesulfonamide as anticancer and radiosensitizers","volume":"80","author":"Ghorab","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bmcl.2025.130416_bb0225","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.bioorg.2016.03.011","article-title":"Design, synthesis and antitumor activity of novel pyrazolo [3, 4-d] pyrimidine derivatives as EGFR-TK inhibitors","volume":"66","author":"Abdelgawad","year":"2016","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bmcl.2025.130416_bb0230","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/jcb.24614","article-title":"IL-33\/IL-31 axis: a new pathological mechanisms for EGFR tyrosine kinase inhibitors-associated skin toxicity","volume":"114","author":"Gangemi","year":"2013","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bmcl.2025.130416_bb0235","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1111\/j.1349-7006.2008.00931.x","article-title":"Clinical significance of pretreatment serum amphiregulin and transforming growth factor-\u03b1, and an epidermal growth factor receptor somatic mutation in patients with advanced non-squamous, non-small cell lung cancer","volume":"99","author":"Masago","year":"2008","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bmcl.2025.130416_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112918","article-title":"Design, synthesis and biological assessment of new selective COX-2 inhibitors including methyl sulfonyl moiety","volume":"209","author":"Sa\u011fl\u0131k","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmcl.2025.130416_bb0245","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10787-017-0342-3","article-title":"Efficacy of phenyl quinoline phenol derivatives as COX-2 inhibitors; an approach to emergent the small molecules as the anti-inflammatory and analgesic therapeutics","volume":"25","author":"Manikandan","year":"2017","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.bmcl.2025.130416_bb0250","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fphar.2019.00091","article-title":"Fluorine-modified rutaecarpine exerts cyclooxygenase-2 inhibition and anti-inflammatory effects in lungs","volume":"10","author":"Lee","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bmcl.2025.130416_bb0255","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.3390\/molecules28186521","article-title":"Development and assessment of 1, 5\u2013diarylpyrazole\/oxime hybrids targeting EGFR and JNK\u20132 as antiproliferative agents: a comprehensive study through synthesis, molecular docking, and evaluation","volume":"28","author":"Abdelrahman","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.bmcl.2025.130416_bb0260","doi-asserted-by":"crossref","first-page":"46265","DOI":"10.1074\/jbc.M207135200","article-title":"Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor","volume":"277","author":"Stamos","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bmcl.2025.130416_bb0265","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1107\/S2053230X16014230","article-title":"Crystal structure of rofecoxib bound to human cyclooxygenase-2","volume":"72","author":"Orlando","year":"2016","journal-title":"Structural Biol Crystal Commun"},{"key":"10.1016\/j.bmcl.2025.130416_bb0270","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bmcl.2025.130416_bb0275","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/384644a0","article-title":"Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents","volume":"384","author":"Kurumbail","year":"1996","journal-title":"Nature"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25003257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25003257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T02:11:05Z","timestamp":1762481465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X25003257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":55,"alternative-id":["S0960894X25003257"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130416","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluation of novel 1,5-diarylpyrazole carboxamides with dual inhibition of EGFR and COX-2 for the treatment of cancer and inflammatory diseases","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130416","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130416"}}